Tenelia

Monotherapy as adjunct to diet & exercise to improve glycemic control in type 2 DM. In combination w/ metformin, sulfonylureas, PPAR agonist (eg, thiazolidinediones), rapid insulin secretagogues, α-glucosidase inhibitors, Na glucose co-transporter 2 (SGLT2) inhibitor, or insulin to improve glycemic control in type 2 DM when single agent alone, w/ diet & exercise, does not provide adequate glycemic control.

Adult 20 mg once daily. May be increased to 40 mg once daily.

May be taken with or without food.

History of hypersensitivity. Severe ketosis, diabetic coma or precoma, type 1 DM. Severe infection, pre- or post-op patients, & patients w/ serious traumatic injury.

Acute pancreatitis. Avoid in patients w/ current or history of QT interval prolongation (congenital long QT syndrome) or history of Torsades de Pointes. Patients w/ cardiac failure (NYHA class III or IV). Hypoglycaemia in patients w/ pituitary or adrenal insufficiency; malnutrition, starvation, irregular diet, insufficient food intake or hyposthenia; extreme muscle exercise; excessive alcohol intake. Intestinal obstruction in patients w/ history of abdominal operation or intestinal obstruction. QT interval prolongation in patients w/ current or history of arrhythmia (eg, severe bradycardia), cardiac disease (eg, CHF), & hypokalaemia. Regularly monitor blood glucose level, amount of food intake & presence/absence of infection during treatment. Concomitant use w/ sulfonylurea or insulin. May impair ability to drive & use machines. Severe hepatic impairment. Pregnancy. Discontinue breastfeeding during treatment. Low-birth-wt infants, neonate, nursing infants or childn. Elderly.

Hypoglycaemia, intestinal obstruction, hepatic impairment, interstitial pneumonia, pemphigoid, acute pancreatitis. Constipation, abdominal distension, discomfort & pain, nausea, flatulence, stomatitis, gastric & colonic polyps, duodenal ulcer, reflux esophagitis, diarrhoea, decreased appetite, increased amylase & lipase; increased AST, ALT & γ-glutamyl transpeptidase; proteinuria, urine ketone body & blood urine present; eczema, rash, itching, allergic dermatitis; increased serum creatine kinase, K & uric acid, malaise, allergic rhinitis.

Increased risk of hypoglycemia w/ sulfonylurea, rapid-acting insulin secretagogues, α-glucosidase inhibitors, biguanides, thiazolidines, glucagon-like peptide-1 receptor agonists, SGLT2 inhibitors, insulin. Decreased blood glucose w/ β-blockers, salicylic acid, MAOIs. Increased blood glucose w/ adrenaline, adrenocortical & thyroid hormones. QT interval prolongation w/ class IA (quinidine sulfate hydrate, procainamide HCl) & class III (amiodarone HCl, sotalol HCl) antiarrhythmics.

Antidiabetic Agents

A10BH08 - teneligliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.

D